Apply Now for AACR Cancer Research Awards

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

The American Association for Cancer Research (AACR) has announced the availability of its four annual research awards. The Gertrude Elion award, provided through an educational grant from Glaxo Wellcome Oncology, is open to nontenured cancer researchers in clinical, basic, or translational research in the United States and Canada.

The American Association for Cancer Research (AACR) has announcedthe availability of its four annual research awards. The GertrudeElion award, provided through an educational grant from GlaxoWellcome Oncology, is open to nontenured cancer researchers inclinical, basic, or translational research in the United Statesand Canada.

The two 1997 Research Fellowships in Clinical/Translational Research,sponsored by Amgen, Inc. and Bristol-Myers Squibb Oncology, andthe 1997 Research Fellowship in Basic Research will go to scientistswho have been postdoctoral or clinical fellows at an academicinstitution in the United States or Canada for at least, but notmore than, 5 years.

A completed application form and sponsorship by an AACR memberare required for each award. The application deadline is February14, 1997. For application forms, contact Jenny Anne Horst-Martzby phone: 215-440-9300; fax: 215-440-9313; or e-mail: aacr@aol.com.

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Panelists smiling at camera on a blue background.
Panelists smiling at camera on a blue background.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Related Content